Faculty COI in Startups: Disclosure Guide

When a faculty member co-founds a startup, or accepts equity, a board seat, or a consulting role in a company that has licensed their own university-developed intellectual property, the resulting conflict of interest is structurally different from most research COI cases. The faculty member is simultaneously the inventor whose disclosure started the licensing process, a research supervisor who may continue to direct sponsored work in the same technical area, and now an owner or officer of the entity that stands to profit from that research. Standard institutional and federal conflict-of-interest frameworks were written for the more common case of outside consulting income or board service; a faculty founder’s situation layers additional, sharper obligations on top of them. This guide covers what has to be disclosed, how institutions build a conflict-of-interest management plan around a faculty founder, why research-oversight separation is usually the central control, and where the federal financial conflict of interest (FCOI) rules from PHS and NSF specifically overlap with — and sometimes diverge from — the institution’s own tech-transfer conflict policy.

For the general disclosure form and process most institutions use across all COI categories, see Conflict of Interest Disclosure Form: What to Include and Sample Structure. For a broader taxonomy of COI types, see Types of Conflict of Interest. This guide focuses specifically on the faculty-founder/equity-holder case that arises once a licensed invention becomes a startup.

Why faculty-founder equity is a distinct COI category

Ordinary outside-activity disclosure (consulting for an unrelated company, sitting on an unrelated advisory board) asks one question: does this outside interest create bias in how the individual does their university job? A faculty founder’s situation asks that question three times over, because the same underlying technology sits at the center of three separate university functions:

Invention disclosure and licensing. The faculty member disclosed the invention to the technology transfer office (TTO) and, if the university elected to retain title under the Bayh-Dole Act, is now the named inventor on a patent the university is licensing to a company the faculty member also owns a stake in. See Invention Disclosure and The Technology Transfer Process for how that pipeline normally works.
Continuing sponsored research. The faculty member may still run a university lab that receives federal or industry funding in the same technical area the startup is commercializing — raising the question of whether university resources, students, or postdocs are effectively subsidizing a private company.
Supervision of trainees. Graduate students and postdocs in the lab may be working on research that is directly relevant to, or even funded in connection with, the startup — while their supervisor has a personal financial stake in that company’s success.

Because all three functions run through the same person and the same technology, institutions generally cannot manage a faculty-founder conflict with disclosure alone. Disclosure identifies the conflict; a written management plan is what actually controls it.

What has to be disclosed

A faculty founder’s disclosure obligations are layered, not singular — they typically span at least three separate mechanisms that don’t automatically talk to each other, so an institution has to route the same underlying fact (equity in the licensee) into all three:

Institutional outside-activity / financial interest disclosure. Most universities require any equity interest, board seat, officer or executive role, consulting arrangement, or royalty stream tied to a company doing business with the university (including a licensee) to be disclosed to a COI office or committee — typically on initial acquisition and then annually, plus an update within a defined window (often 30 days) of any material change such as a new funding round, a new board seat, or a change in the faculty member’s role at the company.
Federal financial conflict of interest (FCOI) disclosure, if the faculty member is an “Investigator” (a term defined broadly — anyone responsible for the design, conduct, or reporting of federally funded research, not just the PI) on a PHS- or NSF-funded project touching the same subject matter. See the PHS and NSF thresholds below — these are separate, statutory disclosure regimes layered on top of the institution’s own policy, not a substitute for it.
Technology-transfer-specific disclosure to the TTO or licensing committee at the point the license is negotiated — because the university is licensing university-owned IP to an entity in which the negotiating faculty member (or a close family member) has a financial stake, most institutions require this to be flagged as a related-party transaction distinct from an arm’s-length license to an unaffiliated company, triggering additional review (see the license-negotiation section below).

The disclosure itself typically covers: the nature and value of the equity or other financial interest, any executive, officer, director, or consulting role at the company, any sponsored-research relationship between the company and the faculty member’s university lab, and whether any of the faculty member’s students, postdocs, or staff perform work for or with the company.

PHS and NSF financial conflict of interest rules: where they overlap and where they diverge

If the faculty member’s related university research is federally funded, institutional COI policy operates alongside — not instead of — the federal FCOI regulations that attach to that specific funding source. The two most common federal regimes a tech transfer office encounters are PHS (including NIH) and NSF, and they use different dollar and equity thresholds, which is a frequent source of confusion when the same faculty member holds appointments or funding touching both.

PHS / NIH — 42 CFR Part 50, Subpart F (and the parallel 45 CFR Part 94 for contracts). A “significant financial interest” (SFI) must be disclosed once aggregated remuneration plus equity value from a publicly traded entity exceeds $5,000 in the prior 12 months. For a non-publicly-traded entity — which describes essentially every early-stage faculty-founded startup — disclosure is required once remuneration exceeds $5,000, or if the investigator holds any equity interest at all, regardless of value. That “any equity” trigger is the detail that catches most faculty founders: a founder’s shares, however small or illiquid, are reportable from day one. Disclosure is required at time of proposal/award, at least annually thereafter, and within 30 days of acquiring a new SFI. The institution’s designated official must determine whether the SFI is FCOI-related to the PHS-funded research and, if so, implement a management plan and report it to the awarding component before award funds are expended.
NSF — Proposal & Award Policies & Procedures Guide (PAPPG), Chapter IX (Recipient Standards). NSF’s conflict-of-interest policy requires disclosure of significant financial interests reasonably related to the funded research, but sets different exclusion thresholds: salary, royalties, or other payments aggregating under $10,000 in the prior 12 months are excluded, and an equity interest is excluded only if it is both under $10,000 in value and represents no more than 5% ownership in the entity. Unlike the PHS rule, NSF’s policy does not carry a blanket “any equity in a non-public company” trigger — but because an early-stage faculty-founder stake is frequently well above 5% ownership, it commonly exceeds the NSF threshold anyway, just via the ownership-percentage test rather than a bright-line dollar amount.

The practical consequence for a tech transfer or research-integrity office: a faculty founder who holds both PHS and NSF funding related to the same startup may clear one agency’s disclosure threshold and not the other, depending on exactly how the equity is structured — so institutional policy generally can’t just adopt one federal threshold as its house standard. Most institutions instead apply their own (often more conservative) internal disclosure threshold across all funding sources, and layer the specific federal management-plan and reporting obligations on top only when PHS or NSF funding is actually in play. See NIH Financial Conflict of Interest (FCOI) Policy and Conflict of Interest Disclosure Form for more on the federal FCOI mechanics generally.

The institutional conflict-of-interest management plan

Once a faculty founder’s equity or other financial interest in the licensee is disclosed and determined to be FCOI-relevant (federally) or otherwise conflicted (under institutional policy), the standard response is not to prohibit the arrangement outright — universities generally want faculty inventors to be able to found companies, and Bayh-Dole’s underlying policy goal is exactly that kind of commercialization — but to put a written management plan in place. A typical plan addresses:

Independent research oversight. A conflict-free co-investigator, department chair, or external monitor reviews study design, data, and results for any sponsored research that touches the startup’s technology, so the faculty founder is not the sole judge of results in which they have a financial stake.
Separation of licensing negotiation from the inventor. The TTO — not the faculty founder — negotiates license terms with the startup, often with an independent valuation or a faculty conflict-of-interest committee reviewing the deal before it’s finalized, precisely because the same person cannot simultaneously represent the university’s interest (favorable license terms) and the company’s interest (favorable terms to itself) in the same negotiation.
Disclosure in publications and to human subjects (if applicable). Any manuscript or presentation arising from related research discloses the equity interest; if the research involves human subjects, many institutions require the COI to be disclosed in the consent process and may require an independent monitor for the IRB-approved protocol. See Conflict of Interest in Human Subjects Research.
Restrictions on procurement and resource use. Limits on the startup purchasing services, materials, or licensed technology from the faculty member’s own university lab, and on the lab providing free or discounted services to the company.
Periodic re-review. Management plans are not one-time documents — they’re revisited at least annually, and immediately if the faculty member’s role at the company changes (for example, moving from a passive equity holder to an officer, or the company entering a new funding round).

In more severe cases — where the conflict cannot be adequately managed, such as the faculty member directly supervising the human-subjects research their company would financially benefit from — the institution may require divestiture of the equity interest, resignation from a company role, or recusal from specific research or oversight functions rather than continuing the conflicted arrangement under a management plan.

Research-oversight separation: the core control

The single most consistent element across faculty-founder management plans is separating the faculty member’s role as a research supervisor from any sponsored research whose outcome could affect the value of their equity. This shows up in a few recurring forms:

No direct supervision of trainees on related sponsored research. A graduate student or postdoc working on federally funded research in the same technical area as the startup typically needs a co-mentor or committee member without a financial stake in the outcome, and evaluation of that trainee’s work (grades, thesis approval, letters of recommendation) should not run solely through the conflicted faculty member.
No unilateral sign-off on data or results. Data that could support (or undermine) the startup’s technology claims is reviewed by someone without an equity stake before it’s finalized in a grant report, manuscript, or regulatory submission.
Clear separation between “university research” and “company work.” Institutions generally require that work performed under a federal award stay clearly distinguishable from work performed for or by the startup — different personnel, different funding streams, different lab notebooks where practicable — partly to protect the university’s own IP position and partly so a federal auditor or program officer can see the line was actually maintained.
Restricted role in award/contract decisions involving the company. The faculty founder does not sit on, or vote in, any university committee or process deciding whether to award funding, space, or resources to their own startup.

This oversight-separation requirement is why a faculty-founder COI plan usually looks structurally different from a plan for, say, undisclosed outside consulting income: the remedy for consulting income is often just disclosure and a dollar cap, while the remedy for founder equity has to reach into who supervises whom and who signs off on what, because the ongoing research relationship — not just the one-time licensing transaction — is where the conflict keeps recurring.

Where this intersects the license itself

The conflict-of-interest question doesn’t end once a management plan is signed — it recurs at each stage of the underlying tech-transfer relationship:

At invention disclosure, the faculty member discloses the technology like any inventor would (see Invention Disclosure), but the TTO may flag the file early for COI review once it becomes apparent a spinout is likely.
At license negotiation, because the licensee is founder-affiliated, most institutions require an independent negotiator, a faculty COI committee sign-off, and often a fair-market-value or comparable-deals analysis to confirm the license terms (royalty rate, equity stake taken by the university, milestone payments) aren’t more favorable to the startup than an arm’s-length deal would be. See License Agreement Structure and Royalty vs. Equity Licensing Compensation for how those terms are typically structured, and Entrepreneurial Resources for University Spinouts and Faculty Founders and Funding Options for a University Spinout for the broader spinout-formation process this conflict review sits inside.
As the company matures and raises outside capital, the faculty founder’s equity stake and role often change (dilution, a board seat, an executive title) — each of which is a disclosure-triggering event under both institutional policy and, where applicable, the 30-day PHS update requirement.

For the difference between the two common spinout structures this whole process can lead to, see Spin-out vs. Spin-off.

How specific institutions structure the COI committee and the license-negotiation firewall

The elements above — a standing committee, a written management plan, and a firewall separating the conflicted faculty member from negotiating on the university’s behalf — are not abstractions; individual research universities publish the specific committee structures and rules that implement them. Three examples, verified against each institution’s own current policy pages:

Duke University routes faculty-startup disclosures to its Institutional Conflict of Interest Committee, which reviews management plans by consent agenda or full review and hears disputes over disclosure decisions. Duke faculty and staff must disclose any financial interest (equity, options, consulting fees) in a university start-up on an annual electronic COI/Conflict of Commitment form and within 30 days of any change. A distinctive Duke control is a time limit rather than an equity limit: full-time faculty with a significant role or interest in a startup must keep outside work for that company to no more than four days per month, averaged annually, and must document the separation between their ongoing university research/teaching and their company work in writing at least annually, reviewed by the department chair and/or dean.
University of Wisconsin-Madison reviews outside activities, including faculty equity in a licensee, through its university-wide Conflict of Interest Committee, a faculty-governance body chaired with roughly 12-18 voting members drawn from the schools and colleges. Patent and equity matters run through a structurally separate channel: inventions are assigned to the Wisconsin Alumni Research Foundation (WARF), a legally independent entity, and go through WARF’s own ownership-and-equity review before a faculty member is free to license or hold equity in the resulting company. Because WARF is organizationally separate from the university, the campus’s own institutional-conflict-of-interest evaluation generally does not need to extend to WARF’s licensing decisions unless university policy specifically says otherwise — an institution-level version of the same separation principle that, at the individual level, keeps the inventor out of their own license negotiation.
Lehigh University requires its Conflict of Interest Review Committee (CIRC) to approve any arrangement in which a faculty member’s startup provides funding to their own Lehigh lab or department, and its technology-transfer policy states plainly that Lehigh faculty and employees may not represent the startup in licensing negotiations with Lehigh’s own Office of Technology Transfer — a direct, named example of the license-review firewall described above. Lehigh’s standard startup license also often takes a minority equity stake (protected from dilution through early funding rounds) in place of a cash licensing fee, which is itself the kind of term an independent, non-conflicted negotiator has to confirm is fair to the university rather than favorable to the founder’s own company.

None of these three publishes a blanket numeric ceiling on how much equity a faculty founder may personally hold — what reads as an “equity cap” in practice is usually one of two different mechanisms: a disclosure/management-plan trigger keyed to the value or percentage of the interest (the PHS “any equity” and NSF 5%-ownership thresholds described above), or, as at Duke, a cap on outside time commitment rather than on ownership itself. Institutions vary in which of these levers they emphasize, but the goal in every case is the same — keep the faculty member’s research-supervision role and their ownership stake from being adjudicated by the same unchecked person.

Frequently asked questions

What has to be disclosed when a faculty member co-founds a startup based on their own university research?

Equity or other financial interest in the company, any officer/director/consulting role, any sponsored-research relationship between the company and the faculty member’s lab, and whether the faculty member’s students or staff perform related work — routed to the institutional COI office, the TTO/licensing process, and, if federal funding touching the same subject matter is involved, the PHS or NSF FCOI disclosure process as well.

Can a faculty founder still supervise graduate students working on related sponsored research?

Generally only with additional controls in place — a conflict-free co-mentor or committee member, independent review of the student’s data and evaluation, and often institutional sign-off confirming the arrangement is adequately managed. Direct, unsupervised oversight of trainees whose work could affect the value of the founder’s equity is the scenario management plans are specifically designed to prevent.

Do the PHS and NSF FCOI equity thresholds match?

No. Under PHS regulations (42 CFR Part 50, Subpart F), any equity interest in a non-publicly-traded entity is reportable regardless of value. Under the NSF PAPPG’s conflict-of-interest policy, an equity interest is excluded from disclosure only if it is both under $10,000 in value and no more than 5% ownership — a threshold structured differently from PHS’s bright-line “any equity” rule, though an early-stage founder’s stake commonly exceeds it anyway via the ownership-percentage test.

Who negotiates the license when the licensee is the inventor’s own startup?

Typically the technology transfer office negotiates on the university’s behalf, not the faculty founder, often with an independent valuation and a faculty conflict-of-interest committee reviewing the final terms — because the same person cannot represent both the university’s and the company’s interests in the same negotiation.

Does the institution ever require divestiture instead of a management plan?

Yes, in cases where the conflict can’t be adequately managed with oversight controls alone — most often where the faculty member would otherwise be the sole supervisor of human-subjects research their company stands to benefit from, or where a management plan’s monitoring requirements can’t realistically be met. Divestiture, resignation from a company role, or recusal from specific oversight functions are the usual alternatives.

Do universities cap how much equity a faculty founder can hold in their own spinout?

Not typically as a blanket ownership-percentage ceiling. The constraint is usually procedural rather than numeric: a disclosure trigger (PHS treats any equity in a non-public licensee as reportable; NSF excludes equity only if it’s both under $10,000 and no more than 5% ownership), a required management plan, and committee review of the license terms. Some institutions instead cap the faculty member’s outside time commitment to the company — Duke, for example, limits full-time faculty to no more than four days per month of outside work for a startup they hold a significant interest in, averaged annually — rather than capping the equity stake itself.

What is a “license-review firewall” and does every university use one?

It’s the practice of keeping the conflicted faculty founder out of the actual negotiation of their own license — the technology transfer office negotiates on the university’s behalf, often with an independent valuation and sign-off from a faculty conflict-of-interest committee. Lehigh University’s policy states this explicitly: faculty and employees may not represent their own startup in licensing negotiations with Lehigh’s technology transfer office. The mechanism is close to universal among research universities with active tech-transfer programs, even where the exact committee name and process differ — Duke’s Institutional COI Committee and the University of Wisconsin-Madison’s Conflict of Interest Committee (with patent/equity matters routed separately through WARF) serve the equivalent function under different names.